NCT06889688 is a Phase 3 clinical trial of Camrelizumab+Apatinib+Eribulin in Breast Cancer Stage IV, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who is sponsoring NCT06889688?

NCT06889688 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT06889688?

Interventions in NCT06889688: Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy.

What condition does NCT06889688 study?

NCT06889688 studies Breast Cancer Stage IV.

Is NCT06889688 still recruiting?

NCT06889688 is currently active, enrolled. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT06889688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Active, enrolled Phase 3 Last updated 15 May 2025

What this trial tests

Phase 3 trial testing Camrelizumab+Apatinib+Eribulin in Breast Cancer Stage IV in 246 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 April 2025

Primary endpoint
20 September 2030

31 March 2031

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	246
Start date	1 April 2025
Primary completion	20 September 2030
Estimated completion	31 March 2031
Sites	6 locations across China

Drugs / interventions tested

Camrelizumab+Apatinib+Eribulin — full drug profile →
Physician's choice chemotherapy — full drug profile →

Conditions studied

Breast Cancer Stage IV — all drugs for Breast Cancer Stage IV →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 70, female only, with Breast Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Translational drugs targeting cancer stem cells in triple-negative breast cancer.
Oliveira FP, Nogueira ML, Galvão AFC, Dias RB, et al · · 2025 · cited 4× · PMID 40687439 · DOI 10.1016/j.omton.2025.201008
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.
Lei H, Fu J, Gu W, Qiao H, et al · · 2026 · PMID 41510186 · DOI 10.1002/mco2.70560

Verify or expand the search:

Other recruiting trials for Breast Cancer Stage IV

Currently open trials in the same condition.

NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07371585 — Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management · Phase 2 · recruiting
NCT06830382 — HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · recruiting
NCT06678269 — A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · Phase 1 · recruiting
NCT06236269 — HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan · Phase 2 · recruiting

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06889688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06889688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing